Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

BACKGROUND: Ipilimumab and vemurafenib have both been shown to improve survival in phase III trials of patients with metastatic melanoma. Although vemurafenib is associated with a rapid onset of activity, responses are often of limited duration. Conversely, responses to ipilimumab take time to devel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ascierto, Paolo A, Simeone, Ester, Giannarelli, Diana, Grimaldi, Antonio M, Romano, Anna, Mozzillo, Nicola
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2012
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3464706/
https://ncbi.nlm.nih.gov/pubmed/22640478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-107
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge